Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

NF-κB Signaling and Inflammation – Drug Repurposing to Treat Inflammatory Disorders?

Version 1 : Received: 17 January 2022 / Approved: 20 January 2022 / Online: 20 January 2022 (11:16:25 CET)

A peer-reviewed article of this Preprint also exists.

Roberti, A.; Chaffey, L.E.; Greaves, D.R. NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders? Biology 2022, 11, 372. Roberti, A.; Chaffey, L.E.; Greaves, D.R. NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders? Biology 2022, 11, 372.

Journal reference: Biology 2022, 11, 372
DOI: 10.3390/biology11030372

Abstract

NF-κB is a central mediator of inflammation, response to DNA damage and oxidative stress. As a result of its central role in so many important cellular processes, NF-κB dysregulation has been implicated in the pathology of important human diseases. NF-κB activation causes inappropriate inflammatory responses in diseases including rheumatoid arthritis (RA) and multiple sclerosis (MS). Thus, modulation of NF-κB signaling is being widely investigated as an approach to treat chronic inflammatory diseases, autoimmunity and cancer. The emergence of COVID-19 in late 2019, the subsequent pandemic and the huge clinical burden of patients with life-threatening SARS-CoV-2 pneumonia led to a massive scramble to repurpose existing medicines to treat lung inflammation in a wide range of healthcare systems. These efforts continue and these efforts continue to be con-troversial. Drug repurposing strategies are a promising alternative to de-novo drug development, as they minimize drug development timelines and reduce the risk of failure due to unexpected side effects. Different experimental approaches have been applied to identify existing medicines which inhibit NF-κB that could be repurposed as anti-inflammatory drugs.

Keywords

Inflammation; NF-κB; drug repurposing; drug development; autoimmunity; COVID-19; multiple sclerosis; rheumatoid arthritis

Subject

MEDICINE & PHARMACOLOGY, Pathology & Pathobiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.